Examkin

Question

Difficulty: HardRheumatology and Immunology

A 34-year-old woman recently diagnosed with diffuse cutaneous systemic sclerosis presents for management of severe Raynaud phenomenon. Over the past month, she has experienced multiple daily episodes of triphasic color changes (pallor, cyanosis, erythema) in her fingers, accompanied by intense throbbing pain. She currently takes no medications. The physician discusses a stepwise treatment plan to reduce the frequency and severity of her vasospastic attacks, emphasizing that therapy will be escalated sequentially if her symptoms remain refractory to the prior intervention.

Arrange the following management steps in the correct guideline-recommended sequence of escalation, starting with the initial foundational intervention and ending with the rescue therapy reserved for refractory, critical digital ischemia.

  1. 1Implement nonpharmacologic measures, including whole-body warming and smoking cessation
  2. 2Initiate an oral dihydropyridine calcium channel blocker (e.g., amlodipine)
  3. 3Add an oral phosphodiesterase-5 (PDE-5) inhibitor (e.g., sildenafil)
  4. 4Administer an intravenous synthetic prostacyclin analog (e.g., epoprostenol)

Answer

The correct sequence for managing systemic sclerosis-associated Raynaud phenomenon is to begin with nonpharmacologic measures, progress to an oral dihydropyridine calcium channel blocker, escalate to a PDE-5 inhibitor if symptoms remain uncontrolled, and reserve intravenous prostanoids for critical, refractory ischemia.
The stepwise management of Raynaud phenomenon in systemic sclerosis is designed to balance vasodilatory efficacy against systemic side effects (primarily hypotension). Nonpharmacologic cold avoidance and smoking cessation form the foundation of therapy. When these fail, dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are the first-line pharmacologic agents. If symptoms persist despite maximal CCB therapy, stepping up to an oral PDE-5 inhibitor (e.g., sildenafil) is recommended. Finally, intravenous prostacyclin analogs (e.g., epoprostenol, iloprost) are the most potent vasodilators but are exclusively reserved for critical ischemia or active digital ulceration refractory to oral therapies due to their invasive route of administration and severe side-effect profile.

Step-by-Step Solution

1
Identify the foundational treatment for all patients with Raynaud phenomenon.
Nonpharmacologic measures (trigger avoidance, smoking cessation) are selected as the initial intervention.
Behavioral modifications can successfully control mild disease and carry no risk of systemic adverse effects like hypotension.
2
Determine the first-line pharmacologic therapy for patients requiring systemic treatment.
Oral dihydropyridine calcium channel blockers are selected as the second step.
CCBs are universally recommended as the safest and most effective initial oral vasodilators for primary and secondary Raynaud phenomenon.
3
Select the appropriate step-up pharmacologic agent for refractory symptoms.
Oral PDE-5 inhibitors are chosen as the third step.
When CCBs are insufficient or poorly tolerated at maximum doses, adding or substituting a PDE-5 inhibitor provides synergistic vasodilation.
4
Identify the definitive rescue therapy for critical ischemia.
Intravenous synthetic prostacyclin analogs are placed last in the sequence.
Due to the need for intravenous access, high cost, and severe systemic side effect profile, prostanoids are strictly reserved for impending gangrene or refractory active digital ulcers.

Key Concept

The management of secondary Raynaud phenomenon in systemic sclerosis follows a stepwise escalation: nonpharmacologic measures → oral calcium channel blockers → oral PDE-5 inhibitors or topical nitrates → intravenous prostanoids (for critical digital ischemia).
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic